Clinical Trials Logo

Clinical Trial Summary

To evaluate the potential usefulness of 68Ga-DOTA-hLAG-3 positron emission tomography/computed tomography (PET/CT) for the evaluation of LAG-3 expression in primary and/or metastatic tumors, compared with histopathological results.


Clinical Trial Description

Participants with cancer underwent 68Ga-DOTA-hLAG-3 PET/CT for an initial assessment. Tumor uptake was quantified by the maximum standard uptake value (SUVmax) and mean SUV (SUVmean). In addition, the LAG-3 expression of lesions was confirmed by histopathological analyzing. The quantitative parameters of 68Ga-DOTA-hLAG-3 PET/CT were compared with histopathological result to evaluate the diagnostic efficacy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05346276
Study type Interventional
Source The First Affiliated Hospital of Xiamen University
Contact Long Sun, PhD
Phone 86 0592-2137077
Email 13178352662@163.com
Status Recruiting
Phase N/A
Start date April 6, 2022
Completion date May 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05637034 - 68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer N/A
Terminated NCT04095091 - Real-time Tumor Localization and Guidance for Radiotherapy Using Ultrasound (US) and Magnetic Resonance (MR)
Recruiting NCT05378425 - A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab Phase 1
Not yet recruiting NCT04723810 - TumorGlow Intraoperative Molecular Imaging (IMI) Phase 1/Phase 2
Recruiting NCT06116032 - Immune Profiling for Cancer Immunotherapy Response
Recruiting NCT06090266 - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT04416165 - Comparison of FDG and FAPI in Patients With Various Types of Cancer N/A
Recruiting NCT05620134 - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer Phase 1/Phase 2
Recruiting NCT04750772 - Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer N/A
Recruiting NCT06022029 - A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. Phase 1
Terminated NCT01358331 - A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) Phase 1
Recruiting NCT06175221 - Autologous TLPO Vaccine Basket Phase 2
Recruiting NCT05661461 - Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment Phase 1
Active, not recruiting NCT04196530 - BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab Phase 1
Not yet recruiting NCT03731390 - GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma Phase 1
Active, not recruiting NCT03491631 - Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06193902 - LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours. Phase 1/Phase 2
Active, not recruiting NCT04528836 - First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05221320 - Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies Phase 2